Navigation Links
Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
Date:4/4/2012

WATERTOWN, Mass., April. 4, 2012 /PRNewswire/ --Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two of its hepatitis C (HCV) programs will be presented at the International Liver Congress™ 2012 (ILC2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.  Oral presentations will discuss Phase 2 results from "Pilot" and "Co-Pilot", which investigated two different interferon-free combination regimens containing ABT-450, the lead candidate from Enanta's collaborative HCV protease inhibitor program with Abbott.  ABT-450 will be included in two additional poster presentations and a third poster presentation will report in vitro data from Enanta's proprietary nucleotide HCV polymerase inhibitor program. Abstracts are available at www.easl.eu.  

Phase 2 Data Highlights

In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment (SVR12) in 93 percent and 95 percent of treatment-naive genotype 1 (GT1) patients.  In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r.  In addition, SVR12 was achieved in 47 percent of patients who were previous non-responders to past HCV treatment.

In a separate study, known as "Pilot", 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).

"The results from Pilot and Co-Pilot showed very encouraging levels of sustained response and suggest that ABT-450 could be an important component in new
'/>"/>

SOURCE Enanta Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
3. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
4. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
5. Enanta Enters Into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)...   Assurex Health, a personalized medicine company ... for behavioral health and chronic pain conditions, today ... equity financing from new and existing investors, according ... Chief Executive Officer. The financing will ... Health,s GeneSight ®  products.  GeneSight,s patented ...
(Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... BLUE BELL, Pa., Feb. 24, 2011 Inovio Pharmaceuticals, Inc. ... development of therapeutic and preventive vaccines against cancers and infectious ... CEO will present a company overview at the Cowen & ... at the Boston Marriott Copley Place in Boston, MA. ...
... 2011 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ... the Citi 2011 Global Health Care Conference in New York ...  Bruce Cozadd, the company,s chairman and chief executive officer, will ... the presentation may be accessed from the Investors section of ...
Cached Medicine Technology:Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference 2Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference 3
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping ... of the models at LunaDress.co.uk come with big discounts, up to ... veil can turn out to be a most exciting memory and ... always bring surprise to a wedding. On the updated fashion blog, ... veils for a big day . , Going out with friends ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... Reporter , MONDAY, March 28 (HealthDay News) -- Radiation ... airline passengers is not a significant health threat, University ... since the U.S. Transportation Safety Administration (TSA) installed full-body ... 486 scanners in 78 U.S. airports, and it plans ...
... Amanda Gardner HealthDay Reporter , MONDAY, March 28 ... traditional exposure therapy may help anxious patients overcome their fear ... exposing people to the thing they fear -- be it ... But while promising, this experimental treatment is not ...
... surgery should be considered earlier in the treatment of ... can result from diabetes, according to an International Diabetes ... the 2nd World Congress on Interventional Therapies for Type ... written by 20 leading experts in diabetes and bariatric ...
... water they pass through and also affect the distribution carbon-dioxide-absorbing ... researchers from UC San Diego and the University of San ... the growth of phytoplankton in the Atlantic sector of the ... Alley" east of the Antarctic Peninsula. Enhanced phytoplankton growth ...
... News) -- Seeing other people scratching can cause your ... The team at Wake Forest Baptist Medical Center investigated ... "It is conceivable that the neuronal networks or mechanisms ... involved in contagious yawning, a phenomenon that is still ...
... the differences in heart disease among women and men ... as gender and ethnicity matter when it comes to ... Transgender People: Building a Foundation for Understanding, a new ... ensure that clinical researchers identify and address the needs ...
Cached Medicine News:Health News:Airport Scanners Appear Safe, Study Finds 2Health News:Airport Scanners Appear Safe, Study Finds 3Health News:Airport Scanners Appear Safe, Study Finds 4Health News:Stress Hormone Might Help Overcome Fear of Heights 2Health News:International Diabetes Federation supports surgery to treat diabetes 2Health News:International Diabetes Federation supports surgery to treat diabetes 3Health News:Icebergs in the Antarctic play important role in carbon cycle 2Health News:Seeing Others Scratch Can Trigger Your Own Itch 2
... I system is a unique ... combines dual width capability with ... roll" design. Specifically developed to ... patients, the easy-to-use Tri-Flex I ...
... offer a wide selection of solutions for ... use. The sterile water for inhalation and ... plastic pour bottles in 500 and 1000mL ... nebulizer kits or can be used alone ...
... FIO 2 500ML 0.9% Sodium Chloride ... provide unmatched performance and ease of use. You ... from 28% to 100% FIO 2 . We ... for inhalation, USP; 0.45% sodium chloride inhalation, USP; ...
... NEBULIZER EMPTY W/AIR ENT 35%-100% FIO2, ... adjustable from 35% to 100%. It has ... immersion-type heater., ,Empty Nebulizers 5007P and ... to 98%. , ,Convenient slip-on heaters ...
Medicine Products: